Skip to main content

Supporting your patients on their journey with resources, information, and financial assistance programs for eligible patients

ForgingBridges | TRUSELTIQ Access and Support program is a source to help patients feel supported on their path with TRUSELTIQ

Our philosophy is Put Patients First. We believe that you, your staff, and your patients should have support and resources to help navigate the treatment journey ahead with TRUSELTIQ.

Remember, your patients are not alone. We are with them every step of the way, regardless of where they are on their treatment journey, to provide support, educational resources, and assistance with affordability obstacles to accessing treatment.

For questions or additional
info, give us a call. Our support team is ready to help

1-888-55BRIDGE
(1-888-552-7434)

Monday-Friday
8 AM-8 PM ET

The support starts here.

We have a team of specialists who coordinate with insurance companies throughout the benefits verification and coverage process. In addition, we offer eligible patients a number of affordability options and work with uninsured or underinsured patients to identify potential insurance coverage options, such as:

Copay Assistance Program
ForgingBridges | TRUSELTIQ Copay Assistance Program— $0 copay for eligible commercially insured patients for their TRUSELTIQ and phosphate binders related to therapy. The savings for the purchase of TRUSELTIQ and phosphate binders will not exceed $40,000 per year. Individuals who are uninsured or cash paying are not eligible for this program
QuickStart Program
ForgingBridges | TRUSELTIQ QuickStart Program— helps patients with insurance delays of >5 days get therapy as quickly as possible
Patient Assistance Program
ForgingBridges | TRUSELTIQ Patient Assistance Program— provides free drug for eligible uninsured and underinsured patients

ForgingBridges | TRUSELTIQ affordability programs are designed to simplify the process and help patients identify potential financial assistance options. With expedited shipping and knowledgeable people on call to assist you, our goal is to get TRUSELTIQ to your patients as soon as possible.

Our program also provides educational support, tools, and resources to help simplify getting started on TRUSELTIQ and provide informative and empowering information about your patient's disease and treatment with TRUSELTIQ, such as:

Starting Treatment Kit with educational information to help the patient get started on their treatment journey

TRUSELTIQ Box
  • Support calls from a pharmacy care team specialist to help patients get started on treatment and for ongoing support
  • Nurse educators on staff who can answer questions your patients may have about treatment with TRUSELTIQ
  • Text message refill reminders to keep patients engaged and on track with therapy

Patient access support starts here. Enroll your patients today

INDICATION AND IMPORTANT
SAFETY INFORMATION

INDICATION

TRUSELTIQ is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Accelerated approval was granted based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and precautions

  • Ocular toxicity: Retinal pigment epithelial detachment (RPED), which may cause blurred vision, occurred in 11% of 351 patients treated with TRUSELTIQ, including patients with asymptomatic RPED, with a median onset of 26 days. Perform comprehensive ophthalmological exam including optical coherence tomography prior to initiating, at 1 month, at 3 months, and then every 3 months during treatment with TRUSELTIQ. Urgently evaluate patients for onset of visual symptoms and follow up every 3 weeks until resolved or TRUSELTIQ is discontinued. Withhold TRUSELTIQ as recommended. Dry eye occurred in 29% of 351 patients; treat with ocular demulcents as needed
  • Hyperphosphatemia and soft tissue mineralization: Hyperphosphatemia, which can lead to soft tissue mineralization, cutaneous calcinosis, non-uremic calciphylaxis, vascular calcification, and myocardial calcification, occurred in 82% of 351 patients treated with TRUSELTIQ, with a median time to onset of 8 days (range 1-349); 83% of 351 patients treated with TRUSELTIQ received phosphate binders. Monitor for hyperphosphatemia throughout treatment. Initiate phosphate-lowering therapy for serum phosphate >5.5 mg/dL; withhold TRUSELTIQ and initiate phosphate-lowering therapy for serum phosphate >7.5 mg/dL; withhold, reduce the dose, or permanently discontinue TRUSELTIQ based on duration and severity of hyperphosphatemia
  • Embryo-fetal toxicity: TRUSELTIQ can cause fetal harm. Advise pregnant women of the potential risk to the fetus; advise females of reproductive potential and men who are partnered with women of reproductive potential to use effective contraception during treatment with TRUSELTIQ and for 1 month after the final dose

Adverse reactions

  • Most common adverse reactions (incidence ≥20%, all grades): nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, blurred vision, and vomiting
  • Most common laboratory abnormalities (incidence ≥20%, all grades): increased creatinine, increased phosphate, decreased phosphate, increased alkaline phosphatase, decreased hemoglobin, increased alanine aminotransferase, increased lipase, increased calcium, decreased lymphocytes, decreased sodium, increased triglycerides, increased aspartate aminotransferase (AST), increased urate, decreased platelets, decreased leukocytes, decreased albumin, increased bilirubin, and decreased potassium

Drug interactions

  • CYP3A inhibitors: Avoid use with strong and moderate CYP3A inhibitors
  • CYP3A inducers: Avoid use with strong and moderate CYP3A inducers
  • Gastric acid–reducing agents: Avoid coadministration with proton pump inhibitors, histamine-2 receptor antagonists (H2RA), and locally acting antacids. If coadministration of H2RA or locally acting antacids cannot be avoided, separate TRUSELTIQ administration
    • H2RA: Take TRUSELTIQ 2 hours before or 10 hours after
    • Locally-acting antacid: Take TRUSELTIQ 2 hours before or 2 hours after

Dosage and administration

  • Prior to initiating TRUSELTIQ: Confirm FGFR2 fusion or rearrangement; perform comprehensive ophthalmic exam including OCT; confirm negative pregnancy test in females of reproductive potential
  • Starting dose: Take TRUSELTIQ orally once daily on Days 1-21 of 28-day cycles; continue treatment until disease progression or unacceptable toxicity. Take TRUSELTIQ on an empty stomach with a glass of water at least 1 hour before or 2 hours after food
    • No renal or hepatic impairment
      • 125 mg (one 100 mg capsule and one 25 mg capsule)
    • Mild and moderate renal impairment (creatinine clearance 30-89 mL/min)
      • 100 mg (one 100 mg capsule)
    • Mild hepatic impairment (total bilirubin >upper limit of normal [ULN] to 1.5 x ULN or AST > ULN)
      • 100 mg (one 100 mg capsule)
    • Moderate hepatic impairment (total bilirubin >1.5 to 3 x ULN with any AST)
      • 75 mg (three 25 mg capsules)
  • Dose modification: Consult the TRUSELTIQ full Prescribing Information for dose modifications and monitoring recommendations for RPED, hyperphosphatemia, and other Grades 3-4 adverse reactions

Please click here for full Prescribing Information.